SCHEMBL1132907

SCHEMBL1132907

CN[C@@H](CO)CN(C)[C@@H](C)c1ccccc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
AGTR1 P30556 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
LPAR1 Q92633 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
KCNK3 O14649 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12608609 0.86 MEN1 (0.38) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL12610445 0.86 MEN1 (0.38) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL12566168 0.85 SCN1A (0.38) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL12566161 0.85 SCN1A (0.38) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL1132428 0.84 CYP2D6 (0.38) CYP2D6CYP2C19MEN1KMT2APOLB
SCHEMBL1132631 0.80 MEN1 (0.40) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL1132632 0.80 MEN1 (0.40) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL1132890 0.80 MEN1 (0.40) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL12608415 0.79 MEN1 (0.42) MEN1KMT2AKDM4EPOLBHTT
SCHEMBL12608447 0.79 MEN1 (0.42) MEN1KMT2AKDM4EPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 CYP2D6 1907/4885CYP2C19 1409/4885MEN1 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.